Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Fineline Cube Sep 8, 2026
Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Fineline Cube Sep 8, 2026
Company

Merck Reports Q3 2023 Financial Results with Mixed Performance Across Segments

Fineline Cube Nov 10, 2023

Germany-based Merck (ETR: MRK) has released its financial results for the third quarter of 2023,...

Company Deals

AimingMed Partners with Becton, Dickinson and Co. to Advance Tumor Precision Medicine

Fineline Cube Nov 10, 2023

AimingMed, a leading provider of tumor precision medicine solutions based in Hangzhou, has announced a...

Company Drug

China’s NMPA Grants Conditional Approval for Juventas’ CAR-T Therapy Inaticabtagene Autoleucel

Fineline Cube Nov 10, 2023

The National Medical Products Administration (NMPA) has conditionally approved the marketing of inaticabtagene autoleucel (CNCT...

Policy / Regulatory

China’s NMPA Officially Seeks Membership in the Pharmaceutical Inspection Co-operation Scheme (PIC/S)

Fineline Cube Nov 10, 2023

The Pharmaceutical Inspection Co-operation Scheme (PIC/S) has announced that China’s National Medical Products Administration (NMPA)...

Company Drug

Eli Lilly’s Zepbound Approved by FDA for Chronic Weight Management in Adults

Fineline Cube Nov 10, 2023

Eli Lilly (NYSE: LLY) has received registration approval from the US Food and Drug Administration...

Company

BeiGene Ltd Reports Q3 2023 Financial Results with 102% YOY Revenue Increase

Fineline Cube Nov 10, 2023

BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has released its financial results for the...

Company Deals Hospital

Danaher Corporation Partners with CHEA to Boost Oncology Centers in Chinese Counties

Fineline Cube Nov 10, 2023

US-based science and technology services giant Danaher Corporation (NYSE: DHR) has entered into a partnership...

Company Drug

Yantai Dongcheng Pharmaceutical Gets Singapore HSA Nod for Phase I Study of 177Lu-LNC1003

Fineline Cube Nov 10, 2023

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced receiving approval from the...

Company Deals

SanegeneBio Partners with Huadong Medicine to Develop RNAi Therapeutics for Metabolic Diseases

Fineline Cube Nov 10, 2023

Suzhou-based RNA interference (RNAi) therapeutics developer SanegeneBio has entered into a partnership with compatriot firm...

Company Drug

Chongqing Lummy Pharmaceutical’s Generic Ramosetron Passes GQCE in China

Fineline Cube Nov 10, 2023

China-based Chongqing Lummy Pharmaceutical Co., Ltd (SHE: 300006) has announced that its generic version of...

Company Deals

Shanghai Qingyun Pharmaceutical Teams Up with Organon at CIIE for Remeron Marketing

Fineline Cube Nov 10, 2023

China’s Shanghai Qingyun Pharmaceutical Technology Co., Ltd has entered into a partnership with US-based Organon...

Company Medical Device

Sino Medical Sciences Technology Secures EU MDR Approval for HT Supreme Drug-Eluting Stent System

Fineline Cube Nov 10, 2023

China-based Sino Medical Sciences Technology Inc., (SHA: 688108) has announced that it has received Medical...

Company Deals

Biosmelt Pharma Partners with Shenzhen Eureka Biotechnology for Cell and Gene Therapy Advancements

Fineline Cube Nov 10, 2023

Shanghai-based cell and gene therapy (CGT) specialist, Biosmelt Pharma, has entered into a partnership with...

Company Deals

Bayer Secures Multiple Procurement Deals at the 6th CIIE

Fineline Cube Nov 10, 2023

At the 6th China International Import Expo (CIIE) in Shanghai, Germany-headquartered Bayer (ETR: BAYN) announced...

Company Deals

ayer Partners with Changzhou Qianhong Bio-pharma to Advance Digestive Health Solutions

Fineline Cube Nov 10, 2023

Germany-headquartered Bayer (ETR: BAYN) has entered into a partnership with China-based Changzhou Qianhong Bio-pharma Co.,...

Company Drug

Sirius Therapeutics Pursues First-in-Human Trial for SRSD107 in Australia

Fineline Cube Nov 10, 2023

Sino-US biotech Sirius Therapeutics has announced its pursuit of Investigational New Drug (IND) approval in...

Company Drug

ImmVira’s MVR-T3011 IV Achieves Positive Outcomes in US Phase I Clinical Study

Fineline Cube Nov 10, 2023

Shenzhen-based biotechnology company ImmVira has announced the successful completion of Phase I clinical studies in...

Company Medical Device

Establishment Labs Receives NMPA Approval for Motiva Silicone Gel-Filled Breast Implants

Fineline Cube Nov 10, 2023

US-based medical technology company Establishment Labs Holdings Inc., (NASDAQ: ESTA) has announced that it has...

Company

AstraZeneca Reports Q3 2023 Revenue Growth and Oncology Milestones

Fineline Cube Nov 10, 2023

UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has released its financial results for the third...

Company Drug

Novartis’ Remibrutinib Meets Milestones in Late-Stage Chronic Spontaneous Urticaria Studies

Fineline Cube Nov 10, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that two late-stage studies for its Bruton’s...

Posts pagination

1 … 497 498 499 … 718

Recent updates

  • Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections
  • China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback
  • Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation
  • CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally
  • Insilico Medicine Partners with Byterna Therapeutics to Build Next‑Generation mRNA AI‑Native R&D Engine – Targeting Circular mRNA Personalized Cancer Vaccines
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Company Deals

Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation

Company Deals

CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.